| Primary |
| Product Used For Unknown Indication |
45.7% |
| Herpes Zoster |
9.8% |
| Drug Use For Unknown Indication |
9.2% |
| Encephalitis Herpes |
3.3% |
| Genital Herpes |
3.3% |
| Herpes Virus Infection |
3.3% |
| Encephalitis |
2.7% |
| Neuroblastoma |
2.7% |
| Pain |
2.7% |
| Herpes Simplex |
2.2% |
| Oral Herpes |
2.2% |
| Acne |
1.6% |
| Epilepsy |
1.6% |
| Glioblastoma Multiforme |
1.6% |
| Multiple Myeloma |
1.6% |
| Prophylaxis |
1.6% |
| Ulcer |
1.6% |
| Apparent Life Threatening Event |
1.1% |
| Encephalitis Brain Stem |
1.1% |
| Hiv Infection |
1.1% |
|
| Drug Ineffective |
17.7% |
| Vomiting |
11.3% |
| Venoocclusive Liver Disease |
8.1% |
| Renal Failure Acute |
6.5% |
| Visual Acuity Reduced |
6.5% |
| Herpes Zoster |
4.8% |
| Psychiatric Symptom |
4.8% |
| Rash |
4.8% |
| Vulvitis |
4.8% |
| Alopecia |
3.2% |
| Drug Hypersensitivity |
3.2% |
| Herpes Virus Infection |
3.2% |
| Live Birth |
3.2% |
| Malaise |
3.2% |
| Therapeutic Response Unexpected |
3.2% |
| Urticaria |
3.2% |
| White Blood Cell Count Decreased |
3.2% |
| Ataxia |
1.6% |
| Atrial Fibrillation |
1.6% |
| Azotaemia |
1.6% |
|
| Secondary |
| Drug Use For Unknown Indication |
14.4% |
| Antiviral Prophylaxis |
12.9% |
| Herpes Zoster |
8.5% |
| Product Used For Unknown Indication |
8.5% |
| Prophylaxis Against Transplant Rejection |
8.2% |
| Prophylaxis |
6.5% |
| Pain |
4.4% |
| Antibiotic Prophylaxis |
3.8% |
| Glioblastoma Multiforme |
3.5% |
| Histiocytosis Haematophagic |
3.5% |
| Burkitt's Lymphoma |
3.2% |
| Antifungal Prophylaxis |
2.6% |
| Diffuse Large B-cell Lymphoma |
2.6% |
| Hiv Infection |
2.6% |
| Multiple Myeloma |
2.6% |
| Procedural Pain |
2.6% |
| Thrombosis Prophylaxis |
2.6% |
| Mycobacterium Avium Complex Infection |
2.4% |
| Hypertension |
2.1% |
| Infection Prophylaxis |
2.1% |
|
| Drug Ineffective |
18.5% |
| Venoocclusive Liver Disease |
15.4% |
| Renal Failure |
9.2% |
| Death |
4.6% |
| Dilatation Intrahepatic Duct Acquired |
4.6% |
| Rash |
4.6% |
| Renal Failure Acute |
4.6% |
| Torsade De Pointes |
4.6% |
| Vomiting |
4.6% |
| Dysgeusia |
3.1% |
| Febrile Neutropenia |
3.1% |
| Herpes Zoster |
3.1% |
| Pregnancy |
3.1% |
| Pyrexia |
3.1% |
| Thrombocytopenia |
3.1% |
| Toxic Epidermal Necrolysis |
3.1% |
| Treatment Failure |
3.1% |
| Alopecia |
1.5% |
| Bacteraemia |
1.5% |
| Bradycardia |
1.5% |
|
| Concomitant |
| Product Used For Unknown Indication |
30.1% |
| Drug Use For Unknown Indication |
12.9% |
| Prophylaxis |
8.3% |
| Multiple Myeloma |
6.6% |
| Pain |
4.5% |
| Infection Prophylaxis |
4.3% |
| Hiv Infection |
3.8% |
| Acute Myeloid Leukaemia |
3.4% |
| Chronic Lymphocytic Leukaemia |
3.4% |
| Non-hodgkin's Lymphoma |
3.4% |
| Antiviral Prophylaxis |
2.6% |
| Prophylaxis Against Graft Versus Host Disease |
2.5% |
| Premedication |
2.3% |
| Diffuse Large B-cell Lymphoma |
1.9% |
| Depression |
1.9% |
| Hypertension |
1.8% |
| Antifungal Prophylaxis |
1.6% |
| Rheumatoid Arthritis |
1.6% |
| Bone Marrow Conditioning Regimen |
1.4% |
| Herpes Zoster |
1.4% |
|
| Vomiting |
11.7% |
| White Blood Cell Count Decreased |
11.7% |
| Pyrexia |
9.5% |
| Thrombocytopenia |
9.2% |
| Weight Decreased |
7.8% |
| Pneumonia |
5.3% |
| Sepsis |
4.6% |
| Tremor |
4.6% |
| Urinary Tract Infection |
4.2% |
| Neutropenic Sepsis |
3.2% |
| Pruritus |
3.2% |
| Renal Failure Acute |
3.2% |
| Wheezing |
3.2% |
| Febrile Neutropenia |
2.8% |
| Inappropriate Antidiuretic Hormone Secretion |
2.8% |
| Respiratory Failure |
2.8% |
| Stevens-johnson Syndrome |
2.8% |
| Pleural Effusion |
2.5% |
| Septic Shock |
2.5% |
| Somnolence |
2.5% |
|
| Interacting |
| Product Used For Unknown Indication |
86.4% |
| Acute Promyelocytic Leukaemia |
4.5% |
| Herpes Zoster |
4.5% |
| Type 2 Diabetes Mellitus |
4.5% |
|
| Drug Interaction |
50.0% |
| Hypoglycaemia |
50.0% |
|
